Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《China Practical Medicine》 2009-17
Add to Favorite Get Latest Update

Primary study on the mechanism of reversal drug-resistance of human breast cancer cell line MCF-7 by Huaier Granule

LI Rong,XIE Sha,ZHANG Li,et al.Shenzhen Second People's Hospital Shenzhen 518035,China  
Objective To investigate the mechanism of the reversal drug-resistance of human breast cancer cell MCF-7 by Huaier Granule.Methods MTT method was used to detect the cell toxicity,drug-resistant multiple and reversing multiple;fluorescent quantitation reverse transcription polymerase chain reaction and immuno-histo-chemical SP staining was used to detect the mRNA level of multidrug resistance 1(mdr1),multidrug resistance-associated protein(MRP)and their corresponding proteins P-gp,MRP expression of drug sensitive cell line MCF-7/S and drug resistant cell line MCF-7/A before and after treated by non-toxicity dose of Huaier Granule,respectively.Results Non-toxicity dose(0.01 mg/ml)of Huaier Granule could significantly reduce the IC 50(5.06 μm)of ADM to the MCF-7/A,compared to the IC 50(25.8 μm)of ADM to the MCF-7/A without reverseing(P0.01),its reversing multiple was 5.1 times.0.01 mg/ml Huaier Granule could remarkably down-regulate the mRNA level of mdr1,MRP and their corresponding proteins P-gp,MRP expression of MCF-7/A,and it showed significant reduction(P0.01)compared to their expression of control group without Huaier Granule treatment.Conclusion Non-toxicity dose of Huaier Granule could reverse the drug-resistance of MCF-7/A,and the reversal mechanism is related to the down-regulation of the mRNA level of mdr1,MRP and their corresponding proteins P-gp,MRP expression.It implied that Huaier Granule could be a potential reversal agent for clinic.
【CateGory Index】: R737.9
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved